FY2024 EPS Estimates for Shattuck Labs Cut by HC Wainwright

Shattuck Labs, Inc. (NASDAQ:STTK) – HC Wainwright reduced their FY2024 earnings per share (EPS) estimates for shares of Shattuck Labs in a research note issued on Thursday, November 14th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings of ($1.54) per share for the year, down from their previous estimate of ($1.41). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Shattuck Labs’ current full-year earnings is ($1.63) per share. HC Wainwright also issued estimates for Shattuck Labs’ Q4 2024 earnings at ($0.46) EPS, FY2025 earnings at ($0.84) EPS, FY2026 earnings at ($0.75) EPS, FY2027 earnings at ($0.87) EPS and FY2028 earnings at ($1.03) EPS.

A number of other analysts have also recently commented on STTK. Needham & Company LLC reaffirmed a “hold” rating on shares of Shattuck Labs in a research note on Thursday, November 14th. Evercore ISI raised Shattuck Labs to a “strong-buy” rating in a research note on Wednesday, October 2nd. Finally, Citigroup cut Shattuck Labs from a “buy” rating to a “neutral” rating and lowered their price target for the company from $8.00 to $2.00 in a research note on Wednesday, October 2nd. Four research analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $8.67.

Shattuck Labs Trading Down 10.5 %

Shares of NASDAQ:STTK opened at $1.11 on Monday. The stock has a market capitalization of $52.74 million, a P/E ratio of -0.72 and a beta of 1.85. Shattuck Labs has a 1-year low of $1.07 and a 1-year high of $11.76. The business has a 50-day moving average price of $2.03 and a two-hundred day moving average price of $4.12.

Hedge Funds Weigh In On Shattuck Labs

Several institutional investors and hedge funds have recently modified their holdings of STTK. Vanguard Group Inc. grew its position in shares of Shattuck Labs by 38.2% in the 1st quarter. Vanguard Group Inc. now owns 1,819,926 shares of the company’s stock valued at $16,270,000 after purchasing an additional 502,860 shares during the period. Renaissance Technologies LLC boosted its position in Shattuck Labs by 83.1% during the 2nd quarter. Renaissance Technologies LLC now owns 392,010 shares of the company’s stock worth $1,513,000 after acquiring an additional 177,910 shares during the last quarter. Bank of New York Mellon Corp boosted its position in Shattuck Labs by 209.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 222,034 shares of the company’s stock worth $857,000 after acquiring an additional 150,340 shares during the last quarter. Pinnacle Associates Ltd. boosted its position in Shattuck Labs by 15.0% during the 2nd quarter. Pinnacle Associates Ltd. now owns 599,423 shares of the company’s stock worth $2,314,000 after acquiring an additional 78,177 shares during the last quarter. Finally, Villere ST Denis J & Co. LLC boosted its position in Shattuck Labs by 83.7% during the 3rd quarter. Villere ST Denis J & Co. LLC now owns 132,600 shares of the company’s stock worth $463,000 after acquiring an additional 60,400 shares during the last quarter. 58.74% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Shattuck Labs

In other Shattuck Labs news, CEO Taylor Schreiber acquired 36,500 shares of the firm’s stock in a transaction that occurred on Monday, October 7th. The stock was acquired at an average cost of $1.21 per share, for a total transaction of $44,165.00. Following the transaction, the chief executive officer now owns 71,002 shares of the company’s stock, valued at $85,912.42. This trade represents a 105.79 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 10.50% of the stock is owned by insiders.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.